Guy Goodwin
FMedSci
Emeritus Professor of Psychiatry
The development of better ways to treat mood disorders
My research interests are in the treatment of bipolar disorder and the application of neuroscience and technology in understanding the neurobiology of mood disorders, with a focus on developing new treatments.
I was formerly W.A.Handley Chair of Psychiatry and head of the University department of Psychiatry (1996-2011).
I am a Fellow of the American College of Neuropsychopharmacology, and have previously held the positions of President of the British Association for Psychopharmacology (2004–2005) and of the European College of Neuropsychopharmacology (ECNP, 2013-2016).
I am an Emeritus Senior Investigator on the faculty of UK National Institute for Health Research (NIHR).
I am a Thomson Reuters highly cited researcher (top 1% in field).
Recent publications
-
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary.
Journal article
Goodwin GM. et al, (2024), Am J Psychiatry, 181, 79 - 81
-
Combining antidepressants and attention bias modification in primary health care (DEPTREAT): Protocol for a pragmatic randomized controlled trial.
Journal article
Landrø NI. et al, (2023), Contemp Clin Trials, 133
-
The psychedelic experience and treatment-resistant depression.
Journal article
Goodwin GM., (2023), World Psychiatry, 22, 420 - 422
-
Reducing intrusive memories after trauma via an imagery-competing task intervention in COVID-19 intensive care staff: a randomised controlled trial.
Journal article
Iyadurai L. et al, (2023), Transl Psychiatry, 13
-
Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing.
Journal article
Dougherty RF. et al, (2023), Psychopharmacology (Berl)